CPC A61K 31/702 (2013.01) [A23L 33/125 (2016.08); A23L 33/13 (2016.08); A23L 33/40 (2016.08); A61K 31/708 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61P 1/12 (2018.01); A61P 31/12 (2018.01); A23V 2002/00 (2013.01); A23V 2200/32 (2013.01); A23V 2200/3202 (2013.01); A23V 2200/324 (2013.01); A23V 2250/284 (2013.01); A61K 2300/00 (2013.01)] | 20 Claims |
1. A synthetic pediatric formula comprising
from about 40 mg/L to about 350 mg/L of at least one of cytidine 5′-monophosphate, uridine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and combinations thereof;
from about 0.01 mg/mL to about 10 mg/mL of at least one of 3′-sialylactose and 6′-sialylactose;
at least one of docosahexaenoic acid and arachidonic acid; and
at least one of lutein, beta-carotene, zeaxanthin, and lycopene;
wherein the synthetic pediatric formula is shelf stable for at least three months.
|